Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2022 | Outperform → Perform | Oppenheimer | |
| 5/5/2022 | $34.00 → $25.00 | Overweight | Cantor Fitzgerald |
| 3/8/2022 | $30.00 → $22.00 | Outperform | SVB Leerink |
| 3/1/2022 | $31.00 → $27.00 | Outperform | RBC Capital |
| 2/23/2022 | $34.00 → $31.00 | Outperform | RBC Capital |
| 12/10/2021 | $33.00 → $31.00 | Perform → Outperform | Oppenheimer |
| 11/4/2021 | $32.00 → $33.00 | Perform | Oppenheimer |
| 11/4/2021 | $35.00 → $40.00 | Buy | HC Wainwright & Co. |
SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13D - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
Oppenheimer downgraded Aurinia Pharma from Outperform to Perform
Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously
SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously
Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated $17.0 million in cash flow from operations in the third quarter and had cash, cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million Reiterates 2024 net product revenue guidance range of $210 to $220 million for fiscal year 2024 Webcast and conference call to
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024. Aurinia's management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. Webcast & Conference Call Details The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 Company announces development strategy for AUR200, its potential next generation pipeline asset for autoimmune diseases targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Company narrows 2024 net product revenue guidance range to $210 to $220 million Confere
10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- Reuters
The Company recommends that shareholders review the recent report from proxy advisor Glass Lewis, which recommends shareholders vote for the re-election to the Board of Directors of all nine incumbent directors.
New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis (LN), which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function. The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adults with active LN. "The data we are presenting at ACR highlight the pivotal role the rheumatology community must play in diagnosing and managing lupus nephritis. Rheu
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further